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Expression of the gene coding for a new breast tumor-associated antigen, H23, was compared to expression of genes coding for pS2, c-erbB2 and 
estrogen receptor (ER). Comparison involved mRNA expression in normal and malignant breast tissues as well as in non-breast umors. Results 
obtained by RNA dot blot and Northern hybridizations howed that expression of the H23 antigen coding gene is a discriminatory marker in 
human breast cancer. It is expressed in 92% of breast tumors whereas 69%, 62% and 56% of breast tumors demonstrate significant mRNA levels 
of c-erbB2, ER and pS2, respectively. Non-malignant or normal breast tissue expresses much lower levels of the H23 antigen mRNA. From the 
comparative analysis presented here it is concluded that the gene coding for H23 antigen furnishes a most useful marker for human breast cancer. 
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1. INTRODUCTION 
The identification of tumor-specific markers is of 
great importance in cancer diagnosis. Several breast 
tumor-associated markers have recently been described 
[l-6] including mucin-like antigens [2,3], pS2 antigen 
[5], erbB2 oncogene [4] and estrogen receptor, ER [6]. 
A gene designated 17.5 [7] coding for the H23 breast 
tumor-associated antigen [ 121, was isolated and 
characterized in Keydar’s laboratory [7] and full-length 
cDNAs coding for various forms of the antigen were 
recently described by Wreschner et al. [8,9]. An inter- 
nal fragment of the gene, designated ‘3b’ [lo], codes 
for multiple 20 amino acid repeats, similar to cDNA 
fragments described by two other groups [3,11]. These 
multiple repeats appear to be highly immunogenic. One 
mAB contained (H23) recognizes an epitope contained 
within the repeat sequence and detects antigen in 91% 
of breast carcinomas [ 121. 
Although all the markers mentioned above (pS2, 
erbB2, ER and the H23 antigen) seem to be breast 
tumor-associated, there are some discrepancies in the 
literature regarding their specificity for breast cancer. 
To evaluate which of these different markers may be 
most significant, their expression levels were analyzed 
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in both malignant and benign breast tumor tissues as 
well as in non-breast tumors. 
2. MATERIALS AND METHODS 
2.1. Tissues 
Tumor and ‘normal’ tissue specimens were obtained from Sheba 
and Sourasky Medical Centers, Tel Aviv. The malignant breast 
tumors (BT) were all adenocarcinomas. The corresponding ‘N’ 
samples (BN) represent ‘normal’ tissue adjacent to the tumor. BF 
designates breast fibroadenomas. Tissue samples (both benign and 
normal) were also obtained from other organs including thyroid, 
stomach, colon, bladder and ovary. 
2.2. RNA extraction 
RNA was extracted from frozen tissues by the guanidium thio- 
cyanate/CsCl method [13]. PolyA+ RNA was purified by oligo dT 
chromatography [14]. 
2.3. Blot hybridization analysis 
RNA dot and Northern blots were prepared according to Maniatis 
[15] using Gelman nylon membranes. Prehybridixation and 
hybridization were performed as described 1151. After washing, blots 
were exposed to Kodak X-ray film for l-7 days. Film densitometry 
was performed with LKB 2222-020 Ultrascan XL 11 laser den- 
sitometer. The amounts of mRNA hybridized with each probe were 
normalized to 18s rRNA present in the same samples as detected by 
hybridization with “P-labeled 18s rRNA cDNA. 
2.4. Plasmids 
The plasmid containing the 3b cDNA fragment was isolated by M. 
Hareuveni [lo]. Plasmids containing inserts of ER and pS2 coding se- 
quences were kindly provided by P. Chambon [16,17]. The plasmid 
recombinant for the erbB2 gene was constructed by T. Yamamoto 
[IS] and kindly provided by Y. Shilo. 
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Fig. 1. Analysis (RNA dot blot) of the HZ3 antigen, pS2, c-erbB2 and ER mRNA expression in breast and thyroid malignant and non-malignant 
tumors. The dot blot was hybridized with: (A) ‘*P-1abeIed 3b cDNA coding for part of the H23 antigen; (B) 32P-labeled pSZ cDNA; (C) 32P-labeled 
c-erbB2 cDNA; (D) 32P-labeIed ER cDNA. The key for samples is as follows: Breast samples: BT, adenocarcinoma; BN, ‘normal’ tissue adjacent 
to the tumor; BF, benign fibroadenoma. Thyroid samples: Tll, toxic adenoma; T13, T14, T16 and T207, follicular adenomas; T208, T229 and 
TM, papillary carcinomas; T189, anaplastic carcinoma; T194, thyroiditis; T235, colloidal nodular; T12, T15 and T219, goiter, 
3. RESULTS 
3.1. Expression of the H23 antigen mRNA 
Fig. 1A shows that H23 antigen mRNA is highly ex- 
pressed in most (9/10) breast carcinoma samples as 
analyzed by RNA dot blotting. The mean level of 
hybrid~ation in malignant breast tumors is about 7 
times higher than in ‘normal’ breast tissues adjacent to 
the biopsied malignant samples. In some cases H23 an- 
tigen mRNA expression is even higher (see for example 
BT12 showing 33-fold increased expression). 
The fibroadenomas BF13 and BF16 (Fig. 1A) show 
levels of H23 antigen mRNA expression comparable to 
those seen in ‘normal’ breast tissues. One breast 
fibroadenoma, BF9, contained H23 antigen mRNA at 
levels about 4-fold higher than that observed in ‘nor- 
mal’ tissues. This sample was obtained from a patient 
who had previously undergone mastectomy of the con- 
tralateral breast because of an adenocarcinoma. 
In non-breast epithelia1 gIandular tissues such as 
benign thyroid samples, H23 antigen mRNA is almost 
undetectable. In contrast, thyroid papillary carcinomas 
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Fig. 2. Northern blot analysis of mRNA expression in breast and non-breast umors. 3Oag of total RNA or 5 pg of polyA?-selected mRNA from 
breast and non-breast umors were electrophoresed on I .4% agarose gel, transferred to nitrocellulase membrane and hybridized with the following 
‘*P-labeled cDNAs: (A) 3b cDNA coding for part of the H23 antigen. Lanes: a, BTlO; b, BNlO; c, BF13; d, T47D cell line; e, BT4; f, BT2; 
g, bladder malignant umor; h, kidney tumor; i, kidney normal tissue; j, stomach carcinoma; k, thyroid anaplastic arcinoma; 1. thyroid papillary 
carcinoma. fBf pS2 cDNA. Lanes: a, BT6, b, BT4 poly_A+; c, BT4 polyA-; d, BTll; e, BT14; f, stomach carcinoma; g, colon tumor; h, colon 
normal rissue; j, bladder tumor; k, bladder normal tissue; I, ovarian as&c ceifs; m, BTf2; n, T190; o, BT1. (C) erbB2 cDNA. Lanes: a, BT2 
polyA*; b, BT2 polyA_; c, BT4 polyA+; d, BT15; e, T208 polyA+; f, Tl6; g, kidney tumor; h, ovarian ascitic ceib. (Df ER cDNA. Lanes: a, 
ovarian tumor; b, ovarian normal tissue; c, T190; d, T194; e, BN2; f, BR; g, BT4; h, BN4; i, BF16; j, BTIS. 
show low, yet detectabte levels of H23 antigen mRNA 
expression. Varying detectable levels of I-I23 antigen 
mRNA are also seen in stomach (Fig. 2A) and colon 
carcinomas (data not shown); in these cases expression 
is 3.5-12 times lower than that observed in breast 
tumors. 
Northern blot analysis (Fig+ 2) demonstrates ignifi- 
cant expression of H23 antigen mRNA in breast 
tumors. The mRNAs are heterogeneous in size, due to 
either individual differences in the number of 60 bp 
repeat units [3,7,8-l 11, or differential splicing events 
193. 
Probing the same RNA dot blot with pS2 cDNA 
shows that expression of the pS2 gene is less specific for 
breast cancer (Fig. 1B). Although pS2 mRNA is mainly 
detected in W23 antigen-positive malignant breast 
tumors, hybridization with pS2 cI3NA is also observed 
in benign breast tumors (fibroadenoma), which are 
H23 antigen mRNA-negative, Similar levels of pS2 
mRNA expression are observed both in breast car- 
cinomas and in malignant and benign thyroid tissues 
(Fig. IB). High expression of pS2 is also noted in 
stomach, colon, bladder and ovarian tumors (Fig, 2B). 
Northern blot analysis demonstrates 0.7 kb pS2 
mRNA in 9 out of 16 breast carcinomas as well as in 
several non-breast umors (Fig. 2B). 
Dot blot analysis of erbB2 mRNA shows s~~nifi~~t 
levels in breast and thyroid tumors (Fig. 1C). Northern 
blot hybridizatidn confirms this observation 
demonstrating the presence of 5 kb erbB2 mRNA in 12 
out of 16 breast carcinoma tissues. Several malignant 
(3/4) and benign (3/I@) thyroid tumors (Fig. 1C) as 
well as kidney and ovarian tumor sampIes have signifi- 
cant expression (Fig. 2C). Increased amounts of erbB2 
mRNA are detected in some samples of stomach, colon 
and lung carcinomas (data not shown). 
Probing the RNA dot blot with ER cDNA shows 
markedly higher levels of ER mRNA expression in 
breast cancer samples than in other tissues analyzed 
(Fig. 1D). In 3 out of 10 breast carcinomas, however, 
ER mRNA is not detected. Low levels of ER are also 
seen in a benign breast fibroadenoma. 
Northern bfot hybridization demonstrates the 
presence of 6.3 kb ER mRNA in 11 out of 16 breast 
carcinomas. This mRNA is also seen in ovarian and 
thyroid papillary tumors (Fig. 2D). 
4, DISCUSSION 
The comparative analysis of H23 antigen, pS2, erbB2 
and ER gene expression revealed that the H23 antigen 
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may be considered a discriminating marker for breast 
cancer. Its increased expression was observed in 92% of 
tested breast carcinomas whereas the erbB2 oncogene 
was expressed only in 69010, ER gene in 62%, and pS2 
gene in 56% of breast tumors. The expression in breast 
cancer of genes coding for ER, pS2 and erbB2, as 
presented here, is, therefore, in good agreement with 
the data obtained by others [4,5,12,19]. 
Although H23 antigen mRNA is also found in some 
non-breast epithelial tumors, such as stomach, thyroid 
and colon, its relative level of expression in these 
malignancies is significantly lower than that observed 
in breast tissue. 
It is not clear why the gene coding for H23 antigen 
mRNA is overexpressed in breast cancer. However, as 
one of the antigen forms is likely a transmembrane 
receptor-like protein [8,9], it may be an element of a 
signal transducing system. Its increased expression in 
breast tumor cells may, therefore, reflect an involve- 
ment in cell growth. 
H23 antigen mRNA was found to be significantly ex- 
pressed in one breast fibroadenoma sample (BF9) 
isolated from a patient with a history of adenocar- 
cinema in the contralateral breast, indicating that in- 
creased H23 antigen expression may precede the 
transformation of a cell to malignancy. 
Overexpression of the pS2 gene is not restricted to 
breast cancer as compared to expression of the H23 an- 
tigen mRNA. Rio et al. [5] consider pS2 a breast 
cancer-specific marker and found that 49% of breast 
carcinomas expressed pS2 antigen. In our study a com- 
parable 56% of breast tumors expressed pS2 mRNA. 
However, we have also observed relatively high levels 
of pS2 expression in bladder and stomach carcinomas, 
ovarian ascitic tumor cells and various thyroid tumors. 
Recently, Rio et al. [20] reported that pS2 antigen is 
also found in normal stomach mucosa. The combined 
data thus show that pS2 gene expression is less specific 
for breast cancer than expression of the H23 antigen 
gene. 
Overexpression of the erbB2 gene in breast cancer 
and its possible clinical significance has been recently 
reported [2,4]. We also found that 69% of breast car- 
cinomas overexpressed erbB2 mRNA. This observation 
is in accordance with others reporting overexpression 
of 5.0 kb erbB2 mRNA in human mammary tumor cell 
lines [22] and in human breast tumors [4,23]. However, 
the specificity of overexpression of erbB2 in human 
breast tumors has been recently questioned [24]. 
Results obtained in this study as well as data published 
by others [4,21,23] show that the c-erbB2 gene is highly 
expressed not only in breast tumors, but also in tumors 
of thyroid, ovarian, colon, stomach and lung origin. 
Since c-erbB2 overexpression is observed in various 
tumors, it might be more a tumor-associated than an 
organ (breast)-specific marker. 
The level of ER gene expression in malignant breast 
tissue has clinical significance. Our analysis reveals that 
62% of breast carcinomas synthesize ER mRNA. 
McGuire and De La Gras [19] also showed that about 
70% of breast tumor patients have detectable levels of 
tumor ER. The amounts of ER mRNA in some tumors 
(BTS, BT12) were up to 15-20-fold higher than those 
observed in normal tissues. However, since ER mRNA 
is detected only in 60-70% of breast tumors, its role as 
a diagnostic tool in breast cancer is limited in com- 
parison to H23 antigen mRNA. The value of ER gene 
expression in predicting the clinical response to hor- 
mone therapy is nevertheless indisputable [25]. 
In conclusion, a comparative analysis of four breast 
cancer-related genes revealed that expression of the 
recently described H23 antigen gene is highly correlated 
with the malignant phenotype of breast cells and 
therefore may be of significant diagnostic value. 
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